Philippe Knoche

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

World Nuclear Association operates an international organization that promotes nuclear power and supports the companies that comprise the global nuclear industry. The company was founded in 1975 and is headquartered in London, the United Kingdom.

Orano Chimie-Enrichissement SASU is a French company that specializes in the enrichment and reprocessing of nuclear fuel. The private company is based in Chatillon, France.

Orano Recyclage SAS engages in the production and transformation of nuclear materials. The company is based in La Hague, France. The French company is ultimately controlled by the Government of France.

Orano Mining SA wholesales ores and metals. The company is based in Courbevoie, France. The French company is a subsidiary ultimately controlled by the Government of France.

The International Council on Mining & Metals is based in London, UK. The British company works towards a safe, just, and sustainable world enabled by responsibly produced minerals and metals. With over 4,000 different minerals, many containing metallic elements, the company works with members and partners to tackle critical problems for industry, people, and the planet. The International Council on Mining & Metals, founded in 2001, is a leadership organization that promotes sustainable industrialization, infrastructure, and innovation.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.